Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Appili Therapeutics Inc., a biopharmaceutical company, has amended its arrangement agreement for the acquisition of its Class A common shares by Aditxt, Inc., extending key deadlines into September 2024. This revision includes a new deadline for Aditxt to complete necessary financing and for holding a special shareholders’ meeting.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
